The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

This study has been withdrawn prior to enrollment.
(Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the ALTITUDE clinical trial found a higher incidence of adverse events.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Kenneth A. Jamerson, University of Michigan
ClinicalTrials.gov Identifier:
NCT01432106
First received: September 8, 2011
Last updated: November 14, 2013
Last verified: November 2013

September 8, 2011
November 14, 2013
February 2011
December 2012   (final data collection date for primary outcome measure)
Mean Change in SBP from baseline to 10 weeks (2 weeks on initial dose & 6 weeks on higher dose) [ Time Frame: 2 weeks on initial dose & 6 weeks on higher dose ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01432106 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome
A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome

Study purpose: African Americans with hypertension and markers of metabolic syndrome (small elevations in blood glucose, triglycerides and or weight) are at a high risk of cardiovascular (heart and blood vessel) problems. There is a circulating factor called angiotensin II that increases risk and may be more important in African Americans who have up to 20 times greater risk of losing kidney function and requiring dialysis. Research Investigators, including those at the University of Michigan, found one drug (Ramipril) that blocks angiotensin II effects significantly and improves kidney function in African Americans.

The purpose of The SAAVE Study is to determine whether the combination of two new blockers (Valsartan and Aliskiren) of angiotensin II, are better able to lower blood pressure, also improve some of the risk factors for cardiovascular problems and provide greater protection to the heart and kidneys.

The specific hypothesis of this proposal is that the combination of Valsartan/Aliskiren will provide incremental reduction in blood pressure when compared to traditional blockade of Renin Angiotensin Aldosterone System (RAAS) with ramipril. As an exploratory analysis, we propose that the blood pressure effect will be associated with suppressing plasma aldosterone levels, preserving the availability of nitric oxide, and preventing the development of insulin resistance. Other variables of interest include changes from baseline in adiponectin, Procollagen 1 and 3, osteopontin, cystatin C, and serum K+. In a nested cohort we will determine the impact of novel dual RAAS blockade on left ventricular remodeling.

Should our hypotheses be proven correct and novel dual RAAS blockade is more effective than ramipril in reducing blood pressure, plasma aldosterone, preserving the availability of nitric oxide, as reflected by an increase in asymmetric dimethly arginine (ADMA) levels, and improves cardiovascular remodeling, this would have important implications for the long term prevention of target organ damage and cardiovascular events in this high risk ethnic group.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Hypertension
  • Metabolic Syndrome
Drug: Aliskerin/Valsartan and Rampiril

Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.

(However, all non-study medication will be manipulated, initially.)

Other Names:
  • Tekturna (Aliskerin)
  • Diovan (Valsartan)
  • Valturna (Aliskerin/Valsartan
  • Altace (Ramipril)
  • Active Comparator: Aliskiren/Valsartan (Valturna)
    Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
    Intervention: Drug: Aliskerin/Valsartan and Rampiril
  • Active Comparator: Ramipril
    Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
    Intervention: Drug: Aliskerin/Valsartan and Rampiril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. African American men or women 18 - 80 years of age.
  2. Appropriate therapy for high blood pressure consisting of no more than 2 antihypertensives.
  3. Patients with at least one marker of Metabolic Syndrome as evidenced by:

    • HDL cholesterol < 35mg/dl (men); < 45 mg/dl (women)
    • Triglycerides > 200mg/dl
    • Fasting Glucose >100mg/dl
    • Waist Circumference: Men >40 inches (102cm); Women > 35 (88cm)
  4. Recent copy of EKG.
  5. Women able to become pregnant must use reliable contraception (e.g. hormonal contraception and double-barrier methods) throughout this study and for one week after the end of this study. Post-menopausal or surgically sterile women.

Exclusion Criteria:

  1. Uncontrolled hypertension.
  2. Organ transplant.
  3. Hypersensitivity to any study medications
  4. Systolic pressure 170 or higher or Diastolic pressure 110 or higher.
  5. Cardiovascular events within last 6 months Stroke, Heart Attack, Stent, or Hospitalization for severe Heart Failure.
  6. Serum potassium greater than 5.0
  7. Heart block without a pacemaker, continuing arrhythmia or valvular heart disease.
  8. Blocked renal artery.
  9. Patients with severe renal impairment (creatinine 1.7 mg/dl for women and 2.0 mg/dl for men and or estimated GFR <30 mL/min) a history of dialysis, nephritic syndrome, or reno-vascular hypertension.
  10. Any condition that may alter medication absorption.
  11. Any condition that may place patient at higher risk from participating in study or will jeopardize the evaluation of efficacy or safety.
  12. Use of any investigational study medications within 30 days of enrollment
  13. Persons unwilling or unable to take regular medications or comply with study protocol.
  14. Pregnant or nursing (lactating) women, or women of childbearing potential (defined as all women physiologically capable of becoming pregnant) who do not use reliable methods of contraception: surgical sterilization, bilateral tubal ligation, hormonal contraception, implantable and oral) and double barrier methods if accepted by local regulatory authority and ethics committee. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
Both
18 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01432106
SPP100AUS20T
No
Kenneth A. Jamerson, University of Michigan
University of Michigan
Novartis Pharmaceuticals
Principal Investigator: Kenneth Jamerson, MD University of Michigan
University of Michigan
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP